Evidence map›Paper›PMID 35580285›Full record

ArticleJCO oncology practice2022

Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care.

Surbhi Sidana, Cristine Allmer, Melissa C Larson, Amylou Dueck, Kathleen Yost, Rahma Warsame, Gita Thanarajasingam, James R Cerhan, Jonas Paludo, S Vincent Rajkumar and 10 more

Open access · greenAbstract read
In one paragraph

Article in JCO oncology practice, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Patient-Reported Outcome Measures (PROMS) in Lymphoma.Current oncology (Toronto, Ont.) · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 2 institutions in 1 country.

Surbhi SidanaDivision of BMT and Cellular Therapy, Stanford University School of Medicine, Stanford, CA.ORCID 0000-0003-3288-7614
Cristine AllmerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Melissa C LarsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.
Amylou DueckDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9912-1085
Kathleen YostSurvey Research Center, Mayo Clinic, Rochester, MN.ORCID 0000-0002-9641-5627
Rahma WarsameDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-0240-0326
Gita ThanarajasingamDivision of Hematology, Mayo Clinic, Rochester, MN.
James R CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0002-7482-178X
Jonas PaludoDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-7350-5531
S Vincent RajkumarDivision of Hematology, Mayo Clinic, Rochester, MN.
Thomas M HabermannDivision of Hematology, Mayo Clinic, Rochester, MN.
Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-6955-9393
Yi LinDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1556-6416
Morie A GertzDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-3853-5196
Thomas WitzigDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4215-6500
Angela DispenzieriDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-8780-9512
Wilson I GonsalvesDivision of Hematology, Mayo Clinic, Rochester, MN.
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0003-1244-6758
Carrie A ThompsonDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0002-4518-2309
Shaji K KumarDivision of Hematology, Mayo Clinic, Rochester, MN.ORCID 0000-0001-5392-9284
Mayo Clinic in Arizona · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
Project 4: Targeting Resistance to T-Cell Directed Therapy in Multiple MyelomaP50CA186781 · NCI · MAYO CLINIC ARIZONA · PI Peter Leif Bergsagel · 2015 to 2026
$25.5M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
Institutional Career Development Core (KL2)KL2TR003143 · NCATS · STANFORD UNIVERSITY · PI ASCH, STEVEN M. · 2019 to 2023
$8.7M
NCATS NIH HHS KL2 TR003143NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA186781NCI NIH HHS U01 CA195568
6 · The paper itself

Abstract

purposePatients' concerns regarding clinical trial (CT) participation include apprehension about side effects, quality of life (QoL), financial burden, and quality of care.

methodsWe prospectively evaluated the experience of patients with multiple myeloma or lymphoma who were treated on CTs (CT group, n = 35) versus patients treated with standard approaches (non-CT group, n = 88) focusing on QoL, financial burden of care, and patients' perception of quality of care over a 1-year period.

resultsThere were no significant differences in any of the patient-reported outcomes in CT versus non-CT groups. We observed an initial decline in overall QoL in the first 3 months across both groups, driven primarily by physical and functional well-being. QoL gradually improved and was above baseline by month 12. Patients reported highest improvement in the functional well-being subdomain. Patients in both groups reported high satisfaction with the quality of care received, and there were no differences in overall satisfaction, communication with team, or access to care. At baseline, 16%-19% of patients reported financial burden, which increased to a peak of 33% in the CT group and to 49% in the non-CT group over the course of 1 year. There was no significant difference in financial burden in the two groups overall. Most of the patients reported getting all the care that was deemed medically necessary in both groups. However, a significant proportion of patients reported having to make other kinds of financial sacrifices because of their cancer (CT group: 33% of patients at baseline and 21%-40% over 1 year; non-CT group: 19% at baseline and 25%-36% over 1 year).

conclusionPatients treated on CTs reported comparable QoL and quality of care with the non-CT group. A high proportion of patients reported financial burden over time in both groups. Our findings can serve as a guide to educate patients regarding CT participation and highlight the need to address the significant financial burden experienced by patients with cancer.

Indexed as

LymphomaMultiple MyelomaClinical Trials as TopicFinancial StressHumansPatient Reported Outcome MeasuresPerceptionQuality of Life

Identifiers

PMID35580285
PMCPMC9377715
OpenAlexW4280530665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.